A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " Anpyo Center

Anpyo Center

Table of Contents

Effective October 1, 2024, Shinyaku Research Center, Inc. and Anpaku Center, Inc. merged, and the merged entity changed its name to TransGenic, Inc.

Source:Transgenic official website (https://transgenic.co.jp/news/2024/10/post-21.php)

Below is a description of the pre-merger information.

Learn more
about TransGenic

Anpyo Center conducts a variety of pharmacological studies related to cardiovascular, allergy, anti-fatigue, and other therapeutic effects.
This section introduces the features of Anpyo Center’s non-clinical pharmacology services, examples of disease models, and related case studies.
Please use this information as a reference when selecting a contract research organization (CRO).

Features of Anpyo Center’s Non-Clinical Testing Services

Extensive Testing Experience

With over 40 years of experience, we have evaluated a wide range of disease models using genetically engineered mice and rats.
Every year, we conduct studies for more than 1,000 clients on diseases such as Parkinson’s disease and myocardial infarction, providing reliable and reproducible data.
Our trusted expertise allows us to support pharmaceutical companies and research institutions seamlessly from early-stage development to clinical trials.

Clear and Supportive Communication

We explain all study details with transparency, easy-to-understand language, minimizing technical misunderstanding.
Our policy is to provide thorough explanations of study objectives, procedures, and expected outcomes, ensuring confidence for clients with no prior non-clinical studies.

One-Stop Service

Our in-house facilities also support environmental toxicity testing. With a wide variety of studies available under one roof, all necessary tests can be completed with a single partner.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Examples of Disease Models at Anpyo Center

It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.

However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.

Below are some examples of disease models offered at Ina Research.

SCP-Induced Mouse Model

This model is used to evaluate learning and memory functions in the central nervous system.
Abnormal behaviors induced by SCP, a muscarinic anticholinergic agent, are considered to represent memory impairment in animals and are used as a preclinical indication to identify compounds that improve brain function.

Accelerated Aging Mouse Model

This lineage-specific model exhibits various aging-related disorders similar to those seen in humans, such as amyloidosis, senile osteoporosis, and learning and memory impairment.
It is widely used to study the biological mechanisms of aging, the onset of age-related diseases, and potential prevention or treatment strategies.

Middle Cerebral Artery Occlusion (MCAO) Model

We offer mice, rats, and monkeys as experimental models of stroke for developing new drugs targeting the acute phase of cerebral infarction.
Neurological symptoms, infarct formation, and changes in cerebral blood flow are observed and measured.

Examples of Non-Clinical Studies at Anpyo Center

No case studies are currently listed on the official website.

Company Information

Anpyo Center provides contract pharmacological studies for cardiovascular, allergy, anti-fatigue, and other therapeutic effects, as well as pharmacodynamic equivalence studies for generic drugs.

Address	582-2 Shio-shinden, Iwata City, Shizuoka Prefecture
Tel	0538-58-1266
Website	https://www.anpyo.co.jp/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us